Conversion Labs, Inc. (CVLB): Price and Financial Metrics


Conversion Labs, Inc. (CVLB): $29.40

0.09 (+0.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CVLB Stock Price Chart Interactive Chart >

Price chart for CVLB

CVLB Price/Volume Stats

Current price $29.40 52-week high $33.02
Prev. close $29.31 52-week low $0.50
Day low $28.55 Volume 473,500
Day high $30.33 Avg. volume 1,046,458
50-day MA $13.85 Dividend yield N/A
200-day MA $7.21 Market Cap 681.52M

Conversion Labs, Inc. (CVLB) Company Bio


Conversion Labs, Inc. operates as a direct response healthcare company that provides over the counter products and prescription medications to consumers worldwide. The company's products include Shapiro MD, a shampoo, conditioner, and leave-in-foamer for treating hair loss; iNR Wellness MD, a nutritional supplement for immune and gut support; RexMD for the treatment of cold sores, mental health, and various other medical conditions faced by men; SOSRx, a telemedicine brand that offers prescription medications and over-the-counter emergency preparation supplies for disaster situations, such as flu epidemics, bacterial outbreaks, bioterrorism and water supply failures, and others; and PDFSimpli, a PDF conversion software enables users to convert, edit, and sign PDF documents. It markets and sells its products through advertisements on Facebook, Google, Amazon, and other social media and e-commerce platforms. The company was formerly known as Immudyne, Inc. and changed its name to Conversion Labs, Inc. in June 2018. Conversion Labs, Inc. was founded in 1994 and is based in New York, New York.


CVLB Latest News Stream


Event/Time News Detail
Loading, please wait...

CVLB Latest Social Stream


Loading social stream, please wait...

View Full CVLB Social Stream

Latest CVLB News From Around the Web

Below are the latest news stories about Conversion Labs Inc that investors may wish to consider to help them evaluate CVLB as an investment opportunity.

15 retailers at risk of default: report

S&P Global Market Intelligence lists 15 retailers as most vulnerable to a default in a new report.

Yahoo | February 18, 2021

Conversion Labs to Present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, has been invited to present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held on February 17-19, 2021. Conversion Labs CEO Justin Schreiber is scheduled to present in a fireside chat on Thursday, February 18 at 1:00 p.m. Eastern time. He will be joined by the company’s chief business officer, Corey Deutsch, for the presentation and virtual one-on-one meetings with institutional analysts and investors throughout the conference. The presentation will be webcast live and available for replay here and via the investor relations section of the company’s website at ConversionLabs.com. Management will discuss the comp...

Yahoo | February 17, 2021

Conversion Labs to become Life MD with launch of new concierge telehealth services

Direct-to-patient telehealth company Conversion Labs ([[CVLB]] +7.2%) said that it will change its name to Life MD later this month, followed by the official launch of its subscription-based primary care and concierge services offering.Upon the name change, the company expects its stock to begin trading under the symbol "LFMD".Life MD will offer...

Seeking Alpha | February 12, 2021

Conversion Labs Expects 2020 Revenue up 205% to Record $38.0 Million, Subscription ARR up 525% to $26.0 Million

NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, reported preliminary unaudited results for its fourth quarter and full year ended December 31, 2020. Revenue for the fourth quarter is expected to total $13.6 million, up 265% from $3.7 million in the fourth quarter of 2019. Revenue for the full year is expected to total $38.0 million, up 205% from $12.5 million in 2019. “Our strong performance in 2020 demonstrated our ability to provide accessible healthcare to an increasing number of patients across the country,” stated Conversion Labs CEO, Justin Schreiber. “We ended the year exceptionally strong, with December revenues hitting a monthly record of $5.1 million, up 321% over December of last year. In fac...

Yahoo | January 19, 2021

Conversion Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical Officer

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and wellness physician and psychiatrist, Dr. Anthony Puopolo, to the new position of chief medical officer. Dr. Puopolo will be responsible for overseeing the company’s rapidly expanding network of state licensed physicians and ensuring that the company is delivering the highest quality of care. He will also work closely with Conversion Labs’ product and marketing teams to optimize the company’s telemedicine offerings and support expansion into new verticals.Dr. Puopolo brings to Conversion Labs more than 20 years of executive and professional healthcare experience, including serving in senior leadership positions at several m...

Yahoo | January 11, 2021

Read More 'CVLB' Stories Here

CVLB Price Returns

1-mo N/A
3-mo N/A
6-mo 372.67%
1-year 1,723.26%
3-year 2,252.00%
5-year 2,205.88%
YTD 350.23%
2020 1,035.65%
2019 -17.86%
2018 -58.82%
2017 29.77%
2016 116.71%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8908 seconds.